Lutris Pharma Presents Additional Positive Data from Its Phase 2 Trial of LUT014 Gel Demonstrating Significant Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at the ESMO Gastrointestinal Cancers Congress 2025
LUT014 Gel Provides a Statistically Significant Benefit Over Placebo for the Treatment of Acneiform Rash Associated With Cetuximab or Panitumumab Therapy For Patients With Advanced Colorectal Cancer TEL AVIV, Israel, July 7, 2025 /PRNewswire/ — Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicities, today announced the presentation








